Free Trial

Illumina (ILMN) Stock Forecast & Price Target

Illumina logo
$101.80 +2.51 (+2.53%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$102.58 +0.78 (+0.77%)
As of 08/22/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Illumina - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
2
Hold
11
Buy
7

Based on 20 Wall Street analysts who have issued ratings for Illumina in the last 12 months, the stock has a consensus rating of "Hold." Out of the 20 analysts, 2 have given a sell rating, 11 have given a hold rating, and 7 have given a buy rating for ILMN.

Consensus Price Target

$124.58
22.38% Upside
According to the 20 analysts' twelve-month price targets for Illumina, the average price target is $124.58. The highest price target for ILMN is $200.00, while the lowest price target for ILMN is $80.00. The average price target represents a forecasted upside of 22.38% from the current price of $101.80.
Get the Latest News and Ratings for ILMN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Illumina and its competitors.

Sign Up

ILMN Analyst Ratings Over Time

TypeCurrent Forecast
8/24/24 to 8/24/25
1 Month Ago
7/25/24 to 7/25/25
3 Months Ago
5/26/24 to 5/26/25
1 Year Ago
8/25/23 to 8/24/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
7 Buy rating(s)
8 Buy rating(s)
9 Buy rating(s)
11 Buy rating(s)
Hold
11 Hold rating(s)
9 Hold rating(s)
10 Hold rating(s)
9 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$124.58$125.11$128.15$151.10
Forecasted Upside22.38% Upside14.46% Upside59.45% Upside15.00% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

ILMN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ILMN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Illumina Stock vs. The Competition

TypeIlluminaMedical CompaniesS&P 500
Consensus Rating Score
2.25
2.79
2.53
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside22.38% Upside13,202.85% Upside9.65% Upside
News Sentiment Rating
Very Positive News

See Recent ILMN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/12/2025Daiwa America
0 of 5 stars
 DowngradeStrong-Buy ➝ Hold
8/12/2025Daiwa Capital Markets
2 of 5 stars
 DowngradeOutperform ➝ Neutral$94.00-0.82%
8/4/2025Stephens
4 of 5 stars
 Set TargetOverweight ➝ Overweight$110.00+12.52%
8/4/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$100.00 ➝ $105.00+8.45%
8/1/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Conor McNamara
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$118.00 ➝ $126.00+30.04%
8/1/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Kyle Mikson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetHold ➝ Hold$99.00 ➝ $105.00+9.19%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luke Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderweight ➝ Underweight$85.00 ➝ $90.00-7.83%
7/28/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Catherine Ramsey
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$84.00 ➝ $105.00-3.93%
7/11/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sung Ji Nam
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeSector Outperform ➝ Sector Perform$125.00+24.94%
7/9/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Patrick Donnelly
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell$85.00 ➝ $80.00-19.41%
7/8/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vijay Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$116.00 ➝ $128.00+31.76%
5/15/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$190.00 ➝ $185.00+129.39%
5/9/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Julia Qin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$120.00 ➝ $85.00+12.20%
5/9/2025Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Subbu Nambi
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$122.00 ➝ $114.00+48.17%
2/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Gupta
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
2/28/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$100.00+12.40%
2/7/2025TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brennan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$177.00 ➝ $140.00+14.01%
11/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$133.00 ➝ $145.00-4.89%
10/17/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$160.00 ➝ $200.00+38.91%
8/28/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$150.00+14.59%
6/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$115.00+10.28%
3/20/2024OTR Global
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingPositive ➝ Mixed
12/15/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Market Perform
12/13/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$175.00+48.76%
12/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Underperform$140.00 ➝ $100.00-14.99%
10/12/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$200.00+49.91%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 11:22 PM ET.


Should I Buy Illumina Stock? ILMN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, August 23, 2025. Please send any questions or comments about these Illumina pros and cons to contact@marketbeat.com.

Illumina
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Illumina, Inc.:

  • Illumina, Inc. reported earnings per share of $1.19 for the latest quarter, exceeding expectations and indicating strong financial performance.
  • The company has a solid return on equity of nearly 29%, suggesting effective management and profitability relative to shareholder equity.
  • Illumina, Inc. has set a positive earnings guidance for FY 2025, projecting earnings per share between 4.450 and 4.55, which may attract investors looking for growth.
  • With a current stock price around $100.80, the shares are trading significantly below their 52-week high of $156.66, potentially offering a buying opportunity for investors.
  • Recent analyst upgrades, including a price target increase from Royal Bank Of Canada to $126.00, reflect positive sentiment and confidence in the company's future performance.

Illumina
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Illumina, Inc. for these reasons:

  • The company's revenue for the latest quarter was down approximately 4.8% year-over-year, indicating potential challenges in maintaining growth.
  • Illumina, Inc. has received mixed ratings from analysts, with a consensus rating of "Hold," suggesting uncertainty about its future performance.
  • Some analysts have lowered their price targets, with JPMorgan reducing theirs to $85.00, which may indicate a lack of confidence in short-term growth prospects.
  • The stock has a relatively high price-to-earnings ratio of about 12.76, which could suggest that it is overvalued compared to its earnings.
  • Market volatility, as indicated by a beta of 1.37, suggests that the stock may be more sensitive to market fluctuations, posing a risk for investors.

ILMN Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Illumina is $124.58, with a high forecast of $200.00 and a low forecast of $80.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 2 sell ratings, 11 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ILMN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.

According to analysts, Illumina's stock has a predicted upside of 22.38% based on their 12-month stock forecasts.

Over the previous 90 days, Illumina's stock had 4 downgrades by analysts.

Analysts like Illumina less than other "medical" companies. The consensus rating for Illumina is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ILMN compares to other companies.


This page (NASDAQ:ILMN) was last updated on 8/24/2025 by MarketBeat.com Staff
From Our Partners